

Supplementary Table S1. Medications taken by the patients at enrollment and newly-initiated treatments during follow-up.

		First examination	Follow-up
Medications of the cardiovascular system	pentoxyphilline (n)	24	4
	thrombocyte aggregation inhibitors (n)	10	4
	calcium channel blockers (n)	9	1
	statins (n)	4	3
	beta-adrenergic blockers (n)	3	3
	angiotensin receptor antagonists (n)	3	1
	angiotensin convertase enzyme inhibitors (n)	2	
	diuretics (n)	2	
	trimetazidine (n)	1	
	alpha-adrenergic blocker (n)	1	
Medications of the respiratory system	salbutamol (n)	3	1
	theophylline (n)	1	
	formoterole (n)	1	
	budesonide (n)	1	
	cyclesonide (n)	1	
Immunosuppressive agents	low dose methylprednisolon (n)	6	2
	azathioprine (n)	4	2
	methotrexate (n)	1	3
	tocilizumab (n)		3
	mycophenolat mofetil (n)		2
Other medications	proton pump inhibitors (n)	21	4
	cholecalciferol (n)	9	16
	calcium carbonate or calcium citrate (n)	6	8
	prokinetics (n)	6	1
	levothyroxine (n)	3	
	sleeping pills (n)	3	1
	tegafur (n)	1	
	metformin (n)	1	1
	clonazepam (n)	1	
	bisphosphonates (n)		3
	denosumab (n)		1

Numbers indicate number of patients within the whole cohort.